Ambrx hires Peter Kiener as Chief Scientific Officer

Brings expertise in development of next-generation biologic therapeutics to US firm

Ambrx, a clinical stage biopharmaceutical firm based in La Jolla, California, US, has appointed Peter Kiener as Chief Scientific Officer.

Kiener brings decades of expertise in the development of next-generation biologic therapeutics to the firm, including multi-specific, antibody based biologics from his former role as President, Chief Executive and Co-Founder of Zyngenia.

Kiener's knowledge is expected to help Ambrx further advance its pipeline of antibody drug conjugate (ADC) and bispecific antibody therapeutics.

Prior to Zyngenia, Kiener was Executive Vice President and Global Head of Biologics Research and Development at MedImmune, the biologics arm of AstraZeneca. He also held multiple positions at Bristol-Myers Squibb over an 18-year period, 10 years of which were spent working on biological therapeutics.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Finance

Chinese consortium to acquire US biotech Ambrx

Group comprises Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech
Research & Development

BMS partners Ambrx in up to US$112m ADC deal

To develop antibody drug candidates for cancer indications
Research & Development

Merck & Co collaborates with Ambrx

Will develop biologic drug conjugates using Ambrx protein technology
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now